1Moake JL. Thrombotic microangiopathies. N Engl J Med,2002,347 :589-600.
2Fontana S, Hovinga JA,Studt JD,et al. Plasma therapy in thromboticthrombocytopenic purpura : review of the literature and the Bern experi-ence in a subgroup of patients with severe acquired ADAMTS-13 defi-ciency. Semin Hematol,2004,41 :48-59.
4Lotta LA,Mariani M,Consonni D,et al. Different clinical severity of firstepisodes and recurrences of thrombotic thrombocytopenic purpura. Br JHaematol,2010,151 :488494.
6Hong MJ,Lee HG,Hur M,et al. Slow but complete resolution of mitomy-cin-induced refractory thrombotic thrombocytopenic purpura after ritux-imab treatment. Korean J Hematol,2011,46:45-48.
7De la Rubia J,Moscard6 F,G6mez MJ,et al. Efficacy and safety of ritux-imab in adult patients with idiopathic relapsing or refractory thromboticthrombocytopenic purpura : results of a Spanish multicenter study. Trans-fus Apher Sci,2010,43:299-303.
9Scully M,McDonald V,Cavenagh J,et al. A phase II study of the safetyand efficacy of rituximab with plasma exchange in acute acquired throm-botic thrombocytopenic purpura. Blood,2011,118:1746-1753.
二级参考文献5
1Tsai HM,Lian EC.Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. New England Journal of Medicine, The . 1998
